These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34958982)

  • 61. The prevalence and disease burden of severe eosinophilic asthma in Japan.
    Nagasaki T; Sato K; Kume N; Oguma T; Sunadome H; Ito I; Izuhara Y; Okamoto K; Kobayashi S; Ohno T; Mizukami A; Kobayashi A; Kaise T; Kuroda T; Mishima M; Matsumoto H
    J Asthma; 2019 Nov; 56(11):1147-1158. PubMed ID: 30822174
    [No Abstract]   [Full Text] [Related]  

  • 62. Definition, Phenotyping of Severe Asthma, Including Cluster Analysis.
    Casanova S; Ahmed E; Bourdin A
    Adv Exp Med Biol; 2023; 1426():239-252. PubMed ID: 37464124
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects.
    Malinovschi A; Fonseca JA; Jacinto T; Alving K; Janson C
    J Allergy Clin Immunol; 2013 Oct; 132(4):821-7.e1-5. PubMed ID: 23890753
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Implication of fraction of exhaled nitric oxide and blood eosinophil count in severe asthma.
    Soma T; Iemura H; Naito E; Miyauchi S; Uchida Y; Nakagome K; Nagata M
    Allergol Int; 2018 Sep; 67S():S3-S11. PubMed ID: 29754974
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort.
    Heaney LG; Perez de Llano L; Al-Ahmad M; Backer V; Busby J; Canonica GW; Christoff GC; Cosio BG; FitzGerald JM; Heffler E; Iwanaga T; Jackson DJ; Menzies-Gow AN; Papadopoulos NG; Papaioannou AI; Pfeffer PE; Popov TA; Porsbjerg CM; Rhee CK; Sadatsafavi M; Tohda Y; Wang E; Wechsler ME; Alacqua M; Altraja A; Bjermer L; Björnsdóttir US; Bourdin A; Brusselle GG; Buhl R; Costello RW; Hew M; Koh MS; Lehmann S; Lehtimäki L; Peters M; Taillé C; Taube C; Tran TN; Zangrilli J; Bulathsinhala L; Carter VA; Chaudhry I; Eleangovan N; Hosseini N; Kerkhof M; Murray RB; Price CA; Price DB
    Chest; 2021 Sep; 160(3):814-830. PubMed ID: 33887242
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Biologics or immunotherapeutics for asthma?
    Tay HL; Foster PS
    Pharmacol Res; 2020 Aug; 158():104782. PubMed ID: 32275962
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Biologic and New Therapies in Asthma.
    Tabatabaian F; Ledford DK; Casale TB
    Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
    Hanania NA; Wenzel S; Rosén K; Hsieh HJ; Mosesova S; Choy DF; Lal P; Arron JR; Harris JM; Busse W
    Am J Respir Crit Care Med; 2013 Apr; 187(8):804-11. PubMed ID: 23471469
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma.
    Lim S; Jatakanon A; Meah S; Oates T; Chung KF; Barnes PJ
    Thorax; 2000 Mar; 55(3):184-8. PubMed ID: 10679535
    [TBL] [Abstract][Full Text] [Related]  

  • 71. How do biologicals and other novel therapies effect clinically used biomarkers in severe asthma?
    Upham JW; Jurak LM
    Clin Exp Allergy; 2020 Sep; 50(9):994-1006. PubMed ID: 32569412
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.
    Green RH; Brightling CE; McKenna S; Hargadon B; Parker D; Bradding P; Wardlaw AJ; Pavord ID
    Lancet; 2002 Nov; 360(9347):1715-21. PubMed ID: 12480423
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical use of biologics for asthma treatment by allergy specialists: A questionnaire survey.
    Kuruvilla M; Ariue B; Oppenheimer JJ; Singh U; Bernstein JA
    Ann Allergy Asthma Immunol; 2020 Oct; 125(4):433-439. PubMed ID: 32629016
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
    Godar M; Blanchetot C; de Haard H; Lambrecht BN; Brusselle G
    MAbs; 2018 Jan; 10(1):34-45. PubMed ID: 29035619
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical utility of fractional exhaled nitric oxide and blood eosinophils counts in the diagnosis of asthma-COPD overlap.
    Takayama Y; Ohnishi H; Ogasawara F; Oyama K; Kubota T; Yokoyama A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2525-2532. PubMed ID: 30174422
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeting of eosinophils in asthma.
    Molfino NA
    Expert Opin Biol Ther; 2012 Jul; 12(7):807-9. PubMed ID: 22500988
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical and inflammatory features of asthma with dissociation between fractional exhaled nitric oxide and eosinophils in induced sputum.
    Crespo A; Giner J; Torrejón M; Belda A; Mateus E; Granel C; Torrego A; Ramos-Barbón D; Plaza V
    J Asthma; 2016 Jun; 53(5):459-64. PubMed ID: 26785727
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg.
    Gelb AF; Taylor CF; Simmons M; Shinar C
    Pulm Pharmacol Ther; 2009 Dec; 22(6):516-21. PubMed ID: 19467341
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pediatric Severe Asthma in the Era of Biologic Treatments.
    Teague WG
    Pediatr Allergy Immunol Pulmonol; 2020 Sep; 33(3):118-120. PubMed ID: 32953228
    [No Abstract]   [Full Text] [Related]  

  • 80. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma.
    Peters MC; Wenzel SE
    Lancet; 2020 Feb; 395(10221):371-383. PubMed ID: 32007172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.